As described previously [22], MIX treatment improved renal physiology by decreasing proteinuria (Figure 1B) and the inflammatory infiltrate and the glomerular injury in the kidney (Figure S3), it decreased splenomegaly, hepatomegaly, and renal hypertrophy (Figure 1C), and plasma levels of anti-dsDNA, anti-cardiolipin, and IFNα (Figure 1D), but did not inhibit the development of hypertension in IMQ-treated mice (Figure 1A). Here, IFNA1 is linked to Hypertension.